Application of an Inclined Settler for Cell Culture-Based Influenza A Virus Production in Perfusion Mode.
continuous harvesting
inclined settler
influenza vaccine
perfusion
suspension cell culture
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
02
2020
accepted:
29
05
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Influenza viruses have been successfully propagated using a variety of animal cell lines in batch, fed-batch, and perfusion culture. For suspension cells, most studies reported on membrane-based cell retention devices typically leading to an accumulation of viruses in the bioreactor in perfusion mode. Aiming at continuous virus harvesting for improved productivities, an inclined settler was evaluated for influenza A virus (IAV) production using the avian suspension cell line AGE1.CR.pIX. Inclined settlers present many advantages as they are scalable, robust, and comply with cGMP regulations, e.g., for recombinant protein manufacturing. Perfusion rates up to 3000 L/day have been reported. In our study, successful growth of AGE1.CR.pIX cells up to 50 × 10
Identifiants
pubmed: 32714908
doi: 10.3389/fbioe.2020.00672
pmc: PMC7343718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
672Informations de copyright
Copyright © 2020 Coronel, Gränicher, Sandig, Noll, Genzel and Reichl.
Références
Adv Biochem Eng Biotechnol. 2002;74:129-69
pubmed: 11991177
BMC Biotechnol. 2011 Sep 01;11:84
pubmed: 21884612
Vaccine. 2019 Nov 8;37(47):7019-7028
pubmed: 31005427
Biotechnol J. 2015 May;10(5):728-40
pubmed: 25903999
Nat Rev Drug Discov. 2015 Mar;14(3):167-82
pubmed: 25722244
Vaccine. 2018 May 24;36(22):3124-3133
pubmed: 29433897
Cytotechnology. 1998 Nov;28(1-3):163-75
pubmed: 19003418
Appl Microbiol Biotechnol. 2018 Oct;102(20):8725-8737
pubmed: 30091043
Appl Microbiol Biotechnol. 2016 Aug;100(16):7181-92
pubmed: 27129532
Appl Microbiol Biotechnol. 2020 Jun;104(11):4877-4888
pubmed: 32291490
Vaccine. 1995 Sep;13(13):1244-50
pubmed: 8578811
Biotechnol Prog. 2013 Jan-Feb;29(1):222-9
pubmed: 23225663
Virology. 1975 Dec;68(2):440-54
pubmed: 128196
Biotechnol Prog. 1990 Nov-Dec;6(6):458-64
pubmed: 1366836
Appl Microbiol Biotechnol. 2012 Jan;93(2):601-11
pubmed: 21915610
Biotechnol Adv. 2018 Jul - Aug;36(4):1328-1340
pubmed: 29738813
Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32
pubmed: 26758296
Biotechnol Prog. 2020 Jan;36(1):e2915
pubmed: 31587517
Biotechnol Bioeng. 2003 Jun 30;82(7):751-65
pubmed: 12701141
Expert Rev Vaccines. 2015;14(9):1181-95
pubmed: 26178380
Vaccine. 2014 May 19;32(24):2770-81
pubmed: 24583003
Front Immunol. 2018 Jul 20;9:1581
pubmed: 30079062
Biotechnol Prog. 2007 Jan-Feb;23(1):225-31
pubmed: 17269692
Biotechnol Prog. 2011 Sep-Oct;27(5):1282-96
pubmed: 21618723
Biologicals. 2008 May;36(3):145-61
pubmed: 18561375
Biotechnol Prog. 2017 Jul;33(4):913-922
pubmed: 28748636
Vaccine. 2019 Nov 8;37(47):7011-7018
pubmed: 31266669
NPJ Vaccines. 2018 Oct 9;3:44
pubmed: 30323955
Expert Rev Vaccines. 2009 Dec;8(12):1681-92
pubmed: 19943763
Biomed Res Int. 2015;2015:504831
pubmed: 25815321
J Biotechnol. 2015 Nov 10;213:3-12
pubmed: 26014522
Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035
pubmed: 30796494
Biotechnol Bioeng. 2012 Dec;109(12):3049-58
pubmed: 22688835